<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01105169</url>
  </required_header>
  <id_info>
    <org_study_id>100106</org_study_id>
    <nct_id>NCT01105169</nct_id>
  </id_info>
  <brief_title>Personalized Prevention of Colorectal Cancer Trial</brief_title>
  <official_title>Investigational Nutrigenetic Studies for Cancer Prevention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <brief_summary>
    <textblock>
      Colorectal cancer is the fourth most common incident cancer and the second most common cause&#xD;
      of cancer death in the United States, with approximately 150,000 new cases and 57,000 deaths&#xD;
      per year. High calcium intake and magnesium may protect against colorectal cancer and&#xD;
      adenoma, however, results have been inconsistent. We found that genetic makeup, associated&#xD;
      with magnesium absorption and re-absorption, significantly interacted with the calcium and&#xD;
      magnesium ratio in relation to the both adenomatous and hyperplastic polyps. Participants who&#xD;
      carried at least one 1482Ile allele (G-&gt;A)of TRPM7 and who consumed diets with a high&#xD;
      calcium/magnesium ratio were at a higher risk of adenoma and hyperplastic polyps than were&#xD;
      participants who did not carry the polymorphism. We hypothesize that the reduction in the&#xD;
      dietary Ca/Mg ratio may change the markers directly related to tumorigenesis. The primary&#xD;
      aims of this study are to conduct a randomized placebo-controlled intervention trial to test&#xD;
      whether reducing the Ca/mg intake ratio through magnesium supplementation has effects on the&#xD;
      related biomarkers. We will also examine whether the effect of modulating Ca/Mg intake ratio&#xD;
      may be more pronounced among those who carry the 1482Ile allele compared those who don't&#xD;
      carry the 1482Ile allele. Results from our study will help to identify people at a high risk&#xD;
      of colorectal adenoma and to develop personalized strategies to prevent occurrence of&#xD;
      colorectal adenoma, and thus, colorectal cancer through dietary change or nutritional&#xD;
      fortification.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The protein expression levels of TRPM7, MLKL in colorectal mucosa</measure>
    <time_frame>12 week (rectal biopsies will be collected at the baseline and the end of the intervention)</time_frame>
    <description>TRPM7 and MLKL have been detected using immunohistochemical (IHC) techniques.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratios of Ki67:BAX, Ki67:TUNEL in rectal epithelial</measure>
    <time_frame>12 week (rectal biopsies will be collected at the baseline and the end of the intervention)</time_frame>
    <description>Ki67:BAX and Ki67:TUNEL have been analyzed using immunohistochemical (IHC) techniques.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Expression of Cox2 in rectal epithelia</measure>
    <time_frame>12 week (rectal biopsies will be collected at the baseline and the end of the intervention)</time_frame>
    <description>Cox2 has been analyzed using immunohistochemical (IHC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum magnesium</measure>
    <time_frame>12 week</time_frame>
    <description>Serum magnesium concentration was determined using 7D70 Magnesium Reagent Kit from Abbot Laboratories (Abbott Park, IL) the assay was conducted at the Vanderbilt Pathology Laboratory Services.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post treatment body magnesium status</measure>
    <time_frame>12 week after treatment</time_frame>
    <description>Body magnesium status obtained using magnesium tolerance test (MTT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulation 25-Hydroxyvitamin D</measure>
    <time_frame>12 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum C-reactive protein concentration</measure>
    <time_frame>12 week</time_frame>
    <description>Assays of CRP for 180 participants were performed using immuno turbidimetric immunoassay based commercial assay kits (Pointe Scientific, Inc, Canton, MI) at Vanderbilt Lipid Laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine excretion of prostaglandin E2 metabolite (PGE-M)</measure>
    <time_frame>12 week</time_frame>
    <description>Urinary PGE-M level was measured using a liquid chromatography/tandem mass spectrometric method at the Integrated Health Sciences Facility Core of the Vanderbilt Center in Molecular Toxicology.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>GG genotype and magnesium treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who have the GG genotype will be assigned to magnesium glycinate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GG genotype and placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants who have the GG genotype will be assigned to placebo group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GA/AA genotype and magnesium treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who have the GA/AA genotype will be assigned to magnesium glycinate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GA/AA genotype and Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants who have the GA/AA genotype will be assigned to placebo group</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Magnesium glycinate</intervention_name>
    <description>Oral administration of magnesium glycinate daily for 12 weeks</description>
    <arm_group_label>GA/AA genotype and magnesium treatment</arm_group_label>
    <arm_group_label>GG genotype and magnesium treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration of identical-appearing placebo daily for 12 weeks</description>
    <arm_group_label>GA/AA genotype and Placebo</arm_group_label>
    <arm_group_label>GG genotype and placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hyperplastic polyp or/and Adenoma cases&#xD;
&#xD;
          -  Polyps free participants with any of the following high risk of colorectal polyps or&#xD;
             cancer: (1) family history of colorectal cancer or polyps; (2) current cigarette&#xD;
             smoker; (3) obesity (BMI≥30 kg/m2); (4) low intake of fiber (lowest fiber intake&#xD;
             quartile: daily intake &lt;16.6g); (5) high intake of red meat and well-done or processed&#xD;
             meat (mutageneity index ≥5852).&#xD;
&#xD;
          -  Participants from the TCPS (IRB # 090235), the TIARS (IRB # 090235), from Vanderbilt&#xD;
             University Hospital or from other resources&#xD;
&#xD;
          -  Consent to be contacted for future studies in TCPS (IRB # 020462), TIARS (IRB#090235)&#xD;
&#xD;
          -  Participants with a calcium intake ≥ 700 mg/day measuring with 24 hour dietary recalls&#xD;
&#xD;
          -  Participants with a calcium intake &lt; 2000 mg/day measuring with 24 hour dietary&#xD;
             recalls&#xD;
&#xD;
          -  Participants with a calcium/magnesium intake ratio &gt; 2.6&#xD;
&#xD;
          -  Participants with known genotype for Thr1482Ile polymorphism in TRPM7&#xD;
&#xD;
          -  Will live in Nashville or surrounding area in the next 6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Intolerance to magnesium glycinate or microcrystalline cellulose (placebo)&#xD;
&#xD;
          -  Chronic renal diseases and hepatic cirrhosis&#xD;
&#xD;
          -  Chronic ischemic heart disease with unstable angina, chronic heart failure at class&#xD;
             III or IV and acute myocardial infarction in the last 6 months&#xD;
&#xD;
          -  Chronic diarrhea&#xD;
&#xD;
          -  Current breastfeeding&#xD;
&#xD;
          -  Current or planned pregnancy&#xD;
&#xD;
          -  Type I diabetes mellitus&#xD;
&#xD;
          -  Pituitary dwarfism&#xD;
&#xD;
          -  Use of digoxin and licorice&#xD;
&#xD;
          -  Current use of blood anticoagulant drugs such as Dicumarol(Warfarin), Clopidogrel&#xD;
             (Plavix), Prasugrel HCl (Efficent), Ticlopidine (Ticlid), Lovenox (Enoxaparin),&#xD;
             Fragmin (Dalteparin), Innohep (Tinzaparin), Eptifibatide (Integrilin), Tyrofiban&#xD;
             (Aggrastat), and Abciximab (Reopro)&#xD;
&#xD;
          -  Current use of lithium carbonate therapy (Eskalith, Lithobid, Lithonate, Lithotabs,&#xD;
             Apo-Lithium carbonate, Apo-Lithium carbonate SR, Carbolth, Duralith, PMS-Lithium&#xD;
             carbonate, PMS-Lithium citrate)&#xD;
&#xD;
          -  Individuals with a history of colon resection or colectomy due to any reason&#xD;
&#xD;
          -  Individuals with any history of cancer other than non-melanoma skin cancer&#xD;
&#xD;
          -  Individual with history of any organ transplantation&#xD;
&#xD;
          -  Individual with a history of gastric bypass due to any reason&#xD;
&#xD;
          -  Individuals with Inflammatory bowel disease&#xD;
&#xD;
          -  Individuals if creatinine clearance is &lt; 50&#xD;
&#xD;
          -  Currently institutionalized&#xD;
&#xD;
          -  Homeless individual (address, telephone etc.)&#xD;
&#xD;
          -  Unable to provide informed consent&#xD;
&#xD;
          -  Any condition that in the opinion of the investigator raises concerns about protocol&#xD;
             compliance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qi Dai, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chang Yu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martha J Shrubsole, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 14, 2010</study_first_submitted>
  <study_first_submitted_qc>April 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2010</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Qi Dai</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Personalized prevention</keyword>
  <keyword>Colorectal cancer</keyword>
  <keyword>Investigational Nutrigenetic Studies</keyword>
  <keyword>Magnesium</keyword>
  <keyword>Gene polymorphism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

